Oppenheimer Asset Management Inc. Buys 8,917 Shares of InfuSystem Holdings, Inc. (NYSE:INFU)

Oppenheimer Asset Management Inc. increased its stake in InfuSystem Holdings, Inc. (NYSE:INFU) by 52.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,042 shares of the company’s stock after buying an additional 8,917 shares during the period. Oppenheimer Asset Management Inc. owned 0.12% of InfuSystem worth $178,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of INFU. Vanguard Group Inc. raised its position in shares of InfuSystem by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 1,083,730 shares of the company’s stock worth $9,288,000 after acquiring an additional 18,432 shares in the last quarter. Wasatch Advisors LP raised its holdings in InfuSystem by 3.4% in the fourth quarter. Wasatch Advisors LP now owns 846,609 shares of the company’s stock worth $8,923,000 after purchasing an additional 27,881 shares in the last quarter. Ranger Investment Management L.P. lifted its position in InfuSystem by 4.7% during the fourth quarter. Ranger Investment Management L.P. now owns 689,842 shares of the company’s stock valued at $7,271,000 after buying an additional 30,835 shares during the period. First Eagle Investment Management LLC boosted its holdings in shares of InfuSystem by 12.7% during the 1st quarter. First Eagle Investment Management LLC now owns 605,235 shares of the company’s stock valued at $5,187,000 after buying an additional 68,021 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of InfuSystem by 6.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 93,899 shares of the company’s stock worth $641,000 after buying an additional 5,391 shares during the period. 71.13% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised shares of InfuSystem from a “buy” rating to a “strong-buy” rating in a research report on Friday.

InfuSystem Stock Performance

InfuSystem stock opened at $6.46 on Monday. InfuSystem Holdings, Inc. has a twelve month low of $5.74 and a twelve month high of $10.99. The company has a current ratio of 2.07, a quick ratio of 1.64 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $137.57 million, a P/E ratio of -646,000.00 and a beta of 1.46.

InfuSystem (NYSE:INFU) last released its earnings results on Thursday, August 8th. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.01). The company had revenue of $33.70 million during the quarter. InfuSystem had a return on equity of 0.70% and a net margin of 0.28%.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.